CA2593035C - Pharmaceutical compositions for treating diseases associated with nf-.kappa.b activity - Google Patents

Pharmaceutical compositions for treating diseases associated with nf-.kappa.b activity Download PDF

Info

Publication number
CA2593035C
CA2593035C CA2593035A CA2593035A CA2593035C CA 2593035 C CA2593035 C CA 2593035C CA 2593035 A CA2593035 A CA 2593035A CA 2593035 A CA2593035 A CA 2593035A CA 2593035 C CA2593035 C CA 2593035C
Authority
CA
Canada
Prior art keywords
kappa
activity
pharmaceutical compositions
diseases associated
treating diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2593035A
Other languages
English (en)
French (fr)
Other versions
CA2593035A1 (en
Inventor
David Wallach
Parameswaran Ramakrishnan
Taisa Shmushkovich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CA2593035A1 publication Critical patent/CA2593035A1/en
Application granted granted Critical
Publication of CA2593035C publication Critical patent/CA2593035C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2593035A 2004-12-27 2005-12-11 Pharmaceutical compositions for treating diseases associated with nf-.kappa.b activity Expired - Fee Related CA2593035C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL16600604A IL166006A0 (en) 2004-12-27 2004-12-27 Pharmaceutical compositions for treating diseases associated with nf-kb activity
IL166006 2004-12-27
PCT/IL2005/001335 WO2006070348A1 (en) 2004-12-27 2005-12-11 PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-κB ACTIVITY

Publications (2)

Publication Number Publication Date
CA2593035A1 CA2593035A1 (en) 2006-07-06
CA2593035C true CA2593035C (en) 2014-10-14

Family

ID=36072106

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2593035A Expired - Fee Related CA2593035C (en) 2004-12-27 2005-12-11 Pharmaceutical compositions for treating diseases associated with nf-.kappa.b activity

Country Status (9)

Country Link
US (1) US8338567B2 (enExample)
EP (1) EP1838347B1 (enExample)
JP (1) JP5686940B2 (enExample)
AU (1) AU2005320905B2 (enExample)
CA (1) CA2593035C (enExample)
ES (1) ES2518340T3 (enExample)
IL (2) IL166006A0 (enExample)
NO (1) NO20073942L (enExample)
WO (1) WO2006070348A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5954728B2 (ja) 2010-01-22 2016-07-20 国立研究開発法人科学技術振興機構 蛋白質の分解活性を測定するためのプローブ試薬
EP3431493A1 (en) * 2013-09-03 2019-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for inducing senescence in cancer
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5843721A (en) 1997-07-03 1998-12-01 Tularik Inc. Nucleic acids encoding human NIK protein
US6265538B1 (en) * 1998-02-27 2001-07-24 The Regents Of The University Of California Inhibitor of the inflammatory response induced by the TNFA and IL-1
ITMI20010402U1 (it) 2001-07-18 2003-01-18 Valerio Leccacorvi Rivestimento per le superfici di una piscina
ATE521707T1 (de) * 2002-04-18 2011-09-15 Yeda Res & Dev Derivate eines nf-kappab induzierenden enzyms, verfahren zur herstellung der derivate und deren verwendung

Also Published As

Publication number Publication date
JP5686940B2 (ja) 2015-03-18
JP2008525427A (ja) 2008-07-17
US20090098106A1 (en) 2009-04-16
NO20073942L (no) 2007-09-27
IL183926A0 (en) 2007-10-31
ES2518340T3 (es) 2014-11-05
CA2593035A1 (en) 2006-07-06
AU2005320905B2 (en) 2011-03-17
US8338567B2 (en) 2012-12-25
IL183926A (en) 2012-02-29
EP1838347A1 (en) 2007-10-03
AU2005320905A1 (en) 2006-07-06
WO2006070348A1 (en) 2006-07-06
IL166006A0 (en) 2006-01-15
EP1838347B1 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
WO2006078463A3 (en) Method for treating cardiovascular disease
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2006036371A3 (en) Combination therapy
WO2007124461A3 (en) Glp-1 compounds
WO2005035584A8 (en) Fully human antibodies against human 4-1bb (cd137)
WO2007028065A3 (en) Chimeric oligomeric compounds for modulation of splicing
WO2001030381A3 (de) Verwendung von csf-1-inhibitoren
WO2007038669A3 (en) Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
WO2007025613A3 (en) Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
WO2007062078A3 (en) Thrombopoietin activity modulating compounds and methods
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2008048648A3 (en) Cb1-modulating compounds and their use
WO2006060809A3 (en) Methods of using [3.2.0] heterocyclic compounds and analogs thereof
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
WO2008031835A3 (en) Method of treating autoimmune diseases using vegf-pathway inhibitors
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
WO2006091841A3 (en) Compositions and their uses directed to il-4r alpha
CA2593035C (en) Pharmaceutical compositions for treating diseases associated with nf-.kappa.b activity
WO2004092379A3 (en) Method for treatment of angiogenic disorders
WO2008011473A3 (en) Compositions and their uses directed to hbxip

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181211